Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2022

01-02-2022 | Insulins | Research Article

Comparison of various basal insulin dose adjustments for inpatients while unable to eat

Authors: Chrysten M. Eberhard, Sarah E. Petite

Published in: International Journal of Clinical Pharmacy | Issue 1/2022

Login to get access

Abstract

Background The American Diabetes Association recommends basal insulin or basal plus correctional insulin regimen for non-critically ill patients with type 2 diabetes mellitus unable to eat. There is limited evidence available examining ideal basal insulin dose reductions in this patient population. Aim This study aimed to determine the percent reduction of maintenance basal insulin that would provide the least hypoglycemic incidence in patients with type 2 diabetes mellitus in the non-intensive care unit setting. Methods This retrospective cohort study evaluated adult patients with type 2 diabetes mellitus prescribed outpatient basal insulin with a minimum unable to eat status of two hours. Patients were divided into four groups; <25%, 25–50%, 51–75%, > 75% of basal insulin administered compared to home dose. The primary endpoint was the incidence of hypoglycemia while unable to eat. Secondary endpoints included incidence of hyperglycemia, severe hypoglycemia, median daily blood glucose and hospital length of stay. Results A total of 173 patients were included. The primary outcome of hypoglycemia (5.9% vs. 8.8% vs. 14.3% vs. 12.3%; P = 0.578) was similar in all groups. There were no differences in hyperglycemia (P = 0.0701), severe hypoglycemia (P = 0.578) and median daily blood glucose (P = 0.428). Patients receiving 25–50% of home basal insulin had the longest unable to eat duration (11.5 h; P = 0.026); however, this was not statistically significant when adjusted using the Bonferroni correction for multiple tests. Conclusions No differences were observed in hypoglycemic events for patients unable to eat receiving various basal insulin dose reductions.
Literature
2.
go back to reference American Diabetes A 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44:S211-S20. American Diabetes A 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44:S211-S20.
3.
go back to reference Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-7.CrossRef Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-7.CrossRef
4.
go back to reference Dhatariya K, Corsino L, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized Patients. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA)2000. ISBN 1580406084. Dhatariya K, Corsino L, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized Patients. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA)2000. ISBN 1580406084.
5.
go back to reference Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 2013;36:2169-74.CrossRef Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 2013;36:2169-74.CrossRef
6.
go back to reference Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-6.CrossRef Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-6.CrossRef
7.
go back to reference Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256 – 61.CrossRef Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256 – 61.CrossRef
8.
go back to reference Demma LJ, Carlson KT, Duggan EW, Morrow JG 3rd, Umpierrez G. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. J Clin Anesth 2017;36:184-8.CrossRef Demma LJ, Carlson KT, Duggan EW, Morrow JG 3rd, Umpierrez G. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. J Clin Anesth 2017;36:184-8.CrossRef
9.
go back to reference Petite SE, Huenecke J, Tuttle N. Evaluation of Basal Insulin Dose Reductions in Hospitalized Patients With Diabetes While Unable to Eat. Hosp Pharm 2020;55:246 – 52.CrossRef Petite SE, Huenecke J, Tuttle N. Evaluation of Basal Insulin Dose Reductions in Hospitalized Patients With Diabetes While Unable to Eat. Hosp Pharm 2020;55:246 – 52.CrossRef
10.
go back to reference Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978 – 82.CrossRef Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978 – 82.CrossRef
11.
go back to reference Ditch K, Moore J. Insulin before surgery (November 2013). Cleve Clin J Med 2014;81:335.CrossRef Ditch K, Moore J. Insulin before surgery (November 2013). Cleve Clin J Med 2014;81:335.CrossRef
12.
go back to reference Dobri GA, Lansang MC. Q: how should we manage insulin therapy before surgery? Cleve Clin J Med 2013;80:702-4.CrossRef Dobri GA, Lansang MC. Q: how should we manage insulin therapy before surgery? Cleve Clin J Med 2013;80:702-4.CrossRef
Metadata
Title
Comparison of various basal insulin dose adjustments for inpatients while unable to eat
Authors
Chrysten M. Eberhard
Sarah E. Petite
Publication date
01-02-2022
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2022
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-021-01314-2

Other articles of this Issue 1/2022

International Journal of Clinical Pharmacy 1/2022 Go to the issue

ACKNOWLEDGEMENT

Thank You Reviewers

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.